Abstract
The pluripotent mesenchymal stem cells (MSC) are common precursors to adipocytes and osteoblasts. Large numbers of extracellular and intracellular signals and transcription factors moderate adipogenesis and osteoblastogenesis. Importantly, between adipogenic and osteogenic lineage commitment and differentiation, differentiation of MSCs into one lineage will inhibit their differentiation toward the other lineage. This balance is regulated by numerous signaling pathways. As we know, the peroxisome-proliferator-activated receptor-γ (PPAR-γ) and Wnt/β-catenin pathway are regarded as the master moderators of adipogenesis and osteogenesis. Moreover, governing the differentiation of MSCs to adipogenesis and osteoblastogenesis has significant implications in diverse areas of human health, from obesity to regenerative medicine to osteoporosis. Rivalry roles have been reported of the two pathways since the downstream products activated by Wnt-5a repress PPAR-γ transactivation through the H3K9 histone methyltransferase protein complexes. This review will discuss the inductive and inhibitive role of PPAR-γ in adipogenesis and osteoblastogenesis respectively, as well as the canonical Wnt/β-catenin pathway.
Keywords: Adipogenesis, differentiation, mesenchymal stem cell, osteogenesis, PPAR, Wnt.
Current Stem Cell Research & Therapy
Title:Cross-Talking Between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation
Volume: 11 Issue: 3
Author(s): Chenyuan Xu, Jing Wang, Tianjie Zhu, Yun Shen, Xiaoshan Tang, Li Fang and Yuanzhi Xu
Affiliation:
Keywords: Adipogenesis, differentiation, mesenchymal stem cell, osteogenesis, PPAR, Wnt.
Abstract: The pluripotent mesenchymal stem cells (MSC) are common precursors to adipocytes and osteoblasts. Large numbers of extracellular and intracellular signals and transcription factors moderate adipogenesis and osteoblastogenesis. Importantly, between adipogenic and osteogenic lineage commitment and differentiation, differentiation of MSCs into one lineage will inhibit their differentiation toward the other lineage. This balance is regulated by numerous signaling pathways. As we know, the peroxisome-proliferator-activated receptor-γ (PPAR-γ) and Wnt/β-catenin pathway are regarded as the master moderators of adipogenesis and osteogenesis. Moreover, governing the differentiation of MSCs to adipogenesis and osteoblastogenesis has significant implications in diverse areas of human health, from obesity to regenerative medicine to osteoporosis. Rivalry roles have been reported of the two pathways since the downstream products activated by Wnt-5a repress PPAR-γ transactivation through the H3K9 histone methyltransferase protein complexes. This review will discuss the inductive and inhibitive role of PPAR-γ in adipogenesis and osteoblastogenesis respectively, as well as the canonical Wnt/β-catenin pathway.
Export Options
About this article
Cite this article as:
Xu Chenyuan, Wang Jing, Zhu Tianjie, Shen Yun, Tang Xiaoshan, Fang Li and Xu Yuanzhi, Cross-Talking Between PPAR and WNT Signaling and its Regulation in Mesenchymal Stem Cell Differentiation, Current Stem Cell Research & Therapy 2016; 11 (3) . https://dx.doi.org/10.2174/1574888X10666150723145707
DOI https://dx.doi.org/10.2174/1574888X10666150723145707 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Current Medicinal Chemistry The Synthetic Oleanane Triterpenoid HIMOXOL Induces Autophagy in Breast Cancer Cells via ERK1/2 MAPK Pathway and Beclin-1 Up-regulation
Anti-Cancer Agents in Medicinal Chemistry Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery An Update of Radiolabeled Bombesin Analogs for Gastrin-Releasing Peptide Receptor Targeting
Current Pharmaceutical Design Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Distinct Dimerization Between α-Lactalbumin and Lysozyme Exhibiting Novel Antimicrobial Activity against Gram-positive and Gram-negative Bacteria
Letters in Drug Design & Discovery Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review
Current Pharmaceutical Design Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Current Medicinal Chemistry The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation
Current Drug Delivery Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets Recent Patents on Antibacterial, Antifungal and Antiviral Properties of Tea
Recent Patents on Anti-Infective Drug Discovery Drug-Drug Interactions of Triazole Antifungal Agents in Multimorbid Patients and Implications for Patient Care
Current Drug Metabolism